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Background: Prevalence of celiac disease in developed countries is assessed about 1:100–1:150. The real
prevalence is unknown because mass screenings are expensive and difficult to organize. Moreover celiac disease
can affect people at every age and studies on asymptomatic subjects at different ages are not comparable. In this
study we wanted to know the real prevalence of celiac disease in children in the Republic of San Marino. We also
analysed concordance of different tests used and costs of mass screening.
Methods: The study started in 1993. From 1993 to 1997 children aged 6, 10 and 14 were screened. Since 1997 only
children aged 6 were monitored, in order to have a homogeneous population. In fact, every child born since 1980
was taken into account. Children were recruited by classroom lists of students for general paediatric examination.
Until 2005 the screening test was based on dosage of antibodies anti-gliadin (AGA) IgA and IgG on venous blood.
Since 2006 these tests were replaced by anti-transglutaminase IgA antibodies (ATTG). Anti-endomysial antibodies
(EMA) were performed if result of any between either AGA or ATTG tests was positive or borderline; if EMA was
positive, then an endoscopy with histological examination was performed to confirm the final diagnosis.
Results: Attendance to paediatric examination was 96%, submission to blood test was 87%. 42 on 5092 (0,8%;
1:125) children resulted affected by celiac disease. Histology always confirmed diagnosis by serology except for two
cases. AGA test (until 2005) yielded 28 on 4304 (0,7% 1:143); ATTG test (since 2006) revealed 14 positive cases on
788 (1,8%; 1:55) leading to a larger percentage of diagnosis. EMA antibodies always confirmed positivity of ATTG.
Conclusions: Prevalence of celiac disease in children of Republic of San Marino is comparable to other
North-European Countries. Sensitivity of ATTG proved much higher than that of anti-gliadin antibodies.
Concordance between ATTG and EMA was 100%. Concordance between serology and histology was
approximately 100%. Cost of screening was yearly about 5000 euros (250 children screened every year).
Keywords: Celiac disease, Antitransglutaminase antibodies, Screening, Children, Prevalence, Antiendomysial antibodies,
Anti gliadin antibodiesPlease see Additional file 1 for translation of the abstract
into an Italian language.
Background
The prevalence of celiac disease in occidental population
is assessed about 1:100–1:150. Prevalence in children is
within 1:200–1:62 when confirmed by histology and
within 1:333–1:52 when assessed by serology only [1]. The* Correspondence: elisagiaco@gmail.com
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distribution, and reproduction in any mediumreal prevalence is unknown because different population
screenings often use different serologic tests. Besides there
are different prevalences depending on ethnic groups. In
North Europe (Scandinavian Counties, Ireland and United
Kingdom) some studies showed a variable prevalence
within 1:100 and 1:66 [2].
Mass population screening for celiac disease has been
often proposed for epidemiological studies but there are
several issues to be considered. First, age of people to be
screened: celiac disease can affect people at every age;
then, costs and arrangement of a population screening;ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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positive for serology and negative for histology), and finally,
low compliance to gluten free diet in silent celiacs (subjects
positive to serology and histology but asymptomatic).
Serological tests used for screening in different studies
are: anti-gliadin antibodies (AGA) IgA or IgG, anti-
transglutaminase antibodies (ATTG) and anti-endomysial
antibodies (EMA). They have a different sensitivity and
specificity.
AGA IgA have a sensitivity of 70-85% and a specificity
of 70-90%. Anti-endomysial antibodies (EMA) and anti-
transglutaminase IgA (ATTG), together, have a sensitivity
more than 95% and a specificity of about 100% [3].
Genetic test HLA DQ2/DQ8 is not a diagnostic test, but
an index of predisposition to celiac disease. The classical
genotype is present in about the 30% of population. It is
used to exclude diagnosis in uncertain cases.
In this article we report the results of a population
screening for celiac disease in scholar aged children of
Republic of San Marino from 1993 to 2009.
Methods
In Republic of San Marino mass population screening of
children started in 1993. At first all children aged 6, 10
and 14 were recruited on classroom lists of schools basis.
During the medical examinations, status of growth, sight,
blood pressure, health of tooth and back were checked,
as usual for school-aged children; in addition to this,
collection of children blood sample was suggested to
parents, together with explanations about celiac disease.
Two paediatric health visitors planned the visits providing
information to parents about the study, explaining that
participation was voluntary, and collected wrote informed
consent. Blood samples were taken in hospital and
analysed by hospital laboratory.
Since 1997 only children aged 6 were recruited; previous
calls to children aged 10 and 14 had been made in order
to screen every child born from 1980 to 1990. We selected
that age because in San Marino children aged 6 start
full-time school, having lunch at school menses.
In each subject total IgA was checked, in order to
exclude congenital deficit. Until 2005 we used AGA IgA e
IgG (manual ELISA test, commercial name “Celikey AGA
IgG and IgA” produced by ALIFAX) as screening test; if
AGA IgA were positive (>12 U/ml), laboratory performed
EMA; if AGA IgA were negative but AGA IgG were
highly positive (>100 U/ml) the child was contacted again
to look for subtle signs and symptoms of celiac disease
(stools, abdominal pains, poor growth, loose of appetite)
or familiarity for celiac disease; also, blood sample was
taken again to repeat AGA and to perform EMA if
indicated (test “IFA Anti-Ema IgA assay”, produced by
SCIMEDX corporation). Thus EMA, which is an expensive
test, was limited to only necessary cases, given the factthat many children had positivity of AGA IgG. If AGA
IgA were negative and AGA IgG <100 U/ml, then the
screening was considered negative. If EMA result was
positive or borderline, an endoscopy with duodenal
biopsy and histological examination were performed
to assess the disease (Figure 1) “Screening from 1993
to 2005”.
Since 2006, antibodies anti-transglutaminase IgA (autho-
matic ELISA test for ALEGRIA instrument, commercial
name “anti-tissue-Transglutaminase IgA”, produced by
ORGENTEC) was adopted, followed by, only if positive,
EMA and AGA. An endoscopic examination with duo-
denal biopsy was made if ATTG were positive (> 8 U/ml)




Attendance to screening program was very high: on a
total of 6383 children recruited, 5880 submitted to
paediatric visit (96%); among them, 5092 accepted blood
sample collection for the screening (87%).
42 on 5092 children resulted affected by celiac disease
(positive serology confirmed by histology), with the whole
prevalence referred to subjects submitted to screening
(born from 1980 to 2003) of 1:125; 0,82% (confidence
interval 0,8095-0,8305).
Children screened with AGA (until 2005) were 4304
and among them we found 28 celiacs; children screened
with ATTG (from 2006) were 788 and we found 14 celiacs:
the percentage of celiacs diagnosed with AGA was 0,7%
(1:143), while the percentage of celiacs identified with
ATTG was 1,8% (1:55), about three times higher (Figure 3)
“Results of screening”.
Our screening revealed 12 children with congenital
IgA deficit, as expected (1:500) [4]. In those cases, we
chose not to go forward with examination.
Case-finding
Since 1993 to 2009 we found 26 celiac children out of
the screening project (case-finding): in 11 children blood
examination was required by paediatrics because of
symptoms like abdominal pain, failure to thrive, persist-
ent diarrhea or refractory anaemia (Hb <9 g/dl), being
these children usually younger than 6 years (i.e. not
included in our recruitment plan for screening). 8 chil-
dren examinations were required due to at least one
first degree relative affected by celiac disease (parents
or brothers, these often diagnosed with population
screening).
5 children resulted negative at screening time and
developed the disease later. 2 of those children had AGA
IgA positive at screening with negative EMA: in 1 case
blood examination was repeated every year and diagnosis
SCREENING from 1993 to 2005 
AGA (IgA, IgG) + total IgA
AGA IgA positive AGA IgA negative - AGA IgG >100 U/ml
EMA Confirmation of AGA IgG, atypical/subtle symptoms
Clinic evaluation (atypical/subtle symptoms, 
familiarity) + repetition of AGA after 3-6 months
EMA negative




MARSH 1-2: follow-up and evaluation in 
a paediatric gastroenterological centre
AGA IgA and IgG 
negatives
STOP      
(no celiac 
disease)
If deficit total IgA: STOP 
(counselling to family)
Figure 1 “Screening from 1993 to 2005”.
Alessandrini et al. Italian Journal of Pediatrics 2013, 39:67 Page 3 of 7
http://www.ijponline.net/content/39/1/67made 4 years later when EMA became positive; in another
case parents refused to repeat blood examination every
year, but when their child was admitted to our department
4 years later because of an acute abdominal pain and
hypertransaminasemia, ATTG, EMA and biopsy resulted
positive.SCREENING fro
ATTG + total Ig







and EMA every 6-12 m
free diet
If symptoms appears or level of ATTG incr
of biopsy after 1-2 years. In borderline c
paediatric gastroenterological
Figure 2 “Screening from 2006 to 2009”.Comparison between AGA IgA, EMA and ATTG antibodies
Since 2006, as we started using ATTG, we diagnosed 14
celiac children by screening project and 13 more by case-
finding, for familiarity or suggestive symptoms. In all cases
we performed ATTG, EMA, AGA IgA and AGA IgG.
ATTG value was >100 U/l in 13 cases (normal < 8 U/ml),m 2006 to 2009
A







STOP (No celiac 
disease)
eases, repetition 
ases refer to a 
 centre.
If deficit total IgA: STOP 
(counselling to family)
RESULTS
From 1993 to 2005 screening with AGA:
4304 children,  28 celiacs 
0,7% (1:143)
42 celiac children  
0,8% (1:125)
5880 attended to visit (96%)
From 2006 to 2009 screening with ATTG: 
788 children, 14 celiacs
1,8% (1:55)
6383 children born from 1980 to 2003 in San Marino
5092 made the screening test (87%)
Figure 3 “Results of screening”.
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cases; low ATTG values often coincided with EMA bor-
derline. All children with ATTG positive had EMA posi-
tive or borderline (index of concordance ATTG and EMA
100%).
In 17 children AGA IgA were normal (63%). In 6
children both AGA IgA and IgG were normal (22%).
Symptomatic children diagnosed after 2006 with ATTG
were 5; 1 had both normal AGA IgA and IgG (20%), 1
had normal AGA IgA and positive AGA IgG (20%).
EMA always confirmed ATTG result.
That means on 5 children (with or without symptoms),
1 would have not received diagnosis without performing
ATTG (or EMA) (Table 1).
Overall prevalence
At the end of 2005, when screening was made with
AGA, in San Marino 41 children were diagnosed to have
celiac disease (28 by screening project and other 13 by
case-finding) on a total of 6.943 resident children born
after 1980. The prevalence of celiac disease was 1:169 or
0.59% (confidence interval 0,5784-0,6015).
At the end of 2009, in San Marino 68 patients were
diagnosed for celiac disease (CD) in their childhood
since 1993, 40 females and 28 males (Ratio F:M = 1,4:1).
Children living in the Republic of San Marino and born
after 1980 were 8.143, the overall prevalence of celiacTable 1 Comparison between ATTG, EMA, AGA IgA, AGA
IgG (since year 2006)
27 CD (14 screening + 13 case-finding) ATTG + and EMA +
TOTAL SYMPTOMATIC (5 patients)
AGA IgA - AGA IgG + (17/27) 63% (1/5) 20%
AGA IgA - AGA IgG - (6/27) 22% (1/5) 20%
The table shows that the 22% of total celiac patients (silent or symptomatic)
and the 20% of symptomatic celiac tested since 2006 had negative AGA IgA
and IgG, so they would have not received the diagnosis without performing
ATTG or EMA. AGA IgG were diagnostic in only 63% of total and 20% of
symptomatic celiacs.disease (considering children diagnosed with screening
and children diagnosed by case-finding) was 1:119 or
0.84% (confidence interval 0,8320-0,8480) (Table 2).
Histological diagnosis was uncertain in 4 cases
(2 in screening and 2 by case-finding)
1) A female aged 6, affected by Turner syndrome,
asymptomatic, submitted to screening. AGA and
EMA antibodies were positive, but histology
completely negative. We performed fraction
gamma-delta T cell receptor, that resulted negative;
the HLA was DQ2DQ8; her father was affected by
celiac disease.
2) A male, little-brother of the girl reported above,
with normal karyotype but affected by mental
retardation and multiple malformations
(vesicoureteral reflux, strabismus, cryptorchidism).
When, at the age of 2, the child was visited for
recurrent abdominal pains, AGA and EMA resulted
positive. Histology resulted negative and so was the
examination of fraction gamma-delta T cell receptor.
The HLA was DQ2DQ8. For that patient and his
sister a paediatric gastroenterological centre suggested
a gluten-free diet, which was started with benefit;
3) A female, aged 6, at first asymptomatic, with
borderline serology at the screening (ATTG 33 U/l,
EMA borderline), histology MARSH 1 and HLA
DQ2; we let her at free diet, but some weeks later
she had persisting diarrhea and hyperactivity; during
this period her father was diagnosed for celiac
disease (with intestinal atrophy). After starting
gluten free diet (suggested by a paediatric
gastroenterological centre), diarrhea and
hyperactivity resolved;
4) A female, aged 6, visited out of our screening plan
for alternating constipation and diarrhea, hyposomia
and recurrent abdominal pain. Serology was highly
positive (ATTG > 100 U/l, EMA positive) but
histology showed a MARSH 1; also in this case,
the gluten-free diet resolved symptoms.
Discussion
As a consequence of the presented screening program it
could be said that “the population screening amplified
the screening itself”. In fact, identification of celiac patients
through screening program lead to check of many asymp-
tomatic subjects simply because of their relationship with
each other. Moreover public awareness about celiac disease
grew up: an association of celiac patients was founded,
more information was available to population and fam-
ily doctors, restaurants started offering special menus
for celiacs, school lunches for celiacs became
mandatory. Doctors with increased awareness towards
Table 2 Overall prevalence of CD in 2005 (AGA) and in 2009 (ATTG)
Population of children born after 1980 CD by screening CD by case-finding CD total Prevalence %
2005 (AGA test) 6.943 28 13 41 1:169 0,59%
+ 4 years + 1.200 + 14 + 13 + 27
2009 (ATTG test) 8.143 42 26 68 1:119 0,84%
The table shows the increasing of diagnosis of celiac disease between children (from 0,59% to 0,84%) after introduction of ATTG (considering children diagnosed
by screening and by case-finding in 4 years).
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sis out of screening program.
The attendance to screening, given all the facts men-
tioned above, was very high compared to similar studies
in Italy [5]. We had a great advantage in being a little
Republic: just seven paediatricians (for the whole popula-
tion aged 0–14) working together in the same hospital
and in strict collaboration with schools. In practice,
screening project took place during already scheduled
ordinary visits and parents were provided with information
by doctors they trusted in, that made parents and children
feel comfortable. Laboratory analysis were committed
locally at the hospital, thus minimizing cost and handling.
For what concerns analysis results, ATTG antibodies
showed to be about three times more sensitive than anti
gliadin in identifying celiac patients, and the possibility
to confirm the diagnosys at this stage is under discussion,
as suggested by some guidelines [6,7], since EMA always
confirmed results of ATTG and is an expensive test.Table 3 Costs of screening
ATTG (€ 15) +
total IgA (€ 5)
EMA (€ 25) +
total IgA (€ 5)
Endoscopies HLA










€ 20000 € 30000 € 2000 € 12000Limitations of the screening program
In our screening project total IgA antibodies of all patients
were measured to exclude a deficiency. In case of IgA
deficiency in asymptomatic children without familial
risk for the disease, it was necessary to minimize invasive
procedures. Consequently, parents were informed about
their children’s benign immunological condition and
not diagnostic result of the screening for celiac disease,
together with the advise to perform further examinations
only if the child would show symptoms or if there was
a first-degree relative affected. Until now, we have not
reported any case of celiac patient with IgA deficiency.
Diagnosis in patients with a positive serology and a
normal or not diagnostic histology (MARSH 1–2) is an
issue of major concern: those patients must be checked
for the genetic susceptibility HLA. If HLA results predis-
posing to disease (potential celiac) a long-term follow-up
is required with repetition of ATTG every 12 months and
further endoscopies. At the moment there are different
guidelines for the follow-up of potential celiacs: some
authors suggest a challenge with large quantity of gluten
before repetition of biopsy, others suggest to perform
the mucosal ATTG. A recent study showed that potential
celiac children followed-up for 3 years developed mucosal
atrophy in one-third of cases [8]. In those cases, a longterm follow-up is mandatory for stating the correct
diagnosis.
Speaking of the compliance to gluten-free diet in
asymptomatic subjects (silent celiacs), a recent study
demonstrated that compliance is good within children
after population screening [9] and that applied to our
patients, too. In adolescence the compliance to diet
decreases, because teenagers have often meals out of
home. In our experience, the mass population screening
increased awareness about celiac disease and that gave
young patients the opportunity of understand the im-
portance of diet.Costs of population screening
We considered an approximate cost of € 15 for ATTG
antibodies, € 25 for EMA antibodies, € 5 for total IgA anti-
bodies, € 11,40 for AGA IgG plus IgA and € 300 for HLA.
In our population, performing ATTG antibodies and
total IgA on an average of 250 children every year costs
yearly about € 5000 which grows up to 11250 euros if
EMA is considered for every child.
To take into account HLA costs, HLA examination
is performed once-in-life for first-degree relatives of
celiac patients: as every year we diagnosed an average
of 4 children (since 2006 with ATTG) and conside-
ring 3 first-degree relatives for each one (parents and
one brother or sister), the cost of HLA analysis is
about € 3600 yearly.
In addition there are costs of endoscopies (€ 200/each).
We did not consider costs for medical visits and labora-
tory workers because the screening program was carried
out during ordinary paediatric visits and serological testing
were performed by hospital laboratory during normal
activity. We also didn’t consider costs for gluten-free
diet (Table 3).
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benefits are not. There are no studies comparing the health
of asymptomatic celiac subjects maintaining a free diet,
towards asymptomatic celiac subjects observing an early
gluten-free diet. A recent study on 32 asymptomatic chil-
dren diagnosed for celiac disease (thanks to a screening
between 2 and 4 years) showed that after 10 years 66%
of children did not show a deterioration of generic
health-related quality of life. The authors concluded that
“long-term follow-up studies are needed to assess possible
long-term complications in untreated, non-symptomatic
celiac disease” [9].
Future perspectives
Some authors proposed not to perform endoscopy and
biopsy on classic symptomatic patients (diarrhea, failure to
thrive, malabsorption) with high levels of ATTG (>100 U/l)
[6]. Those patients after some months of a gluten-free diet
have the resolution of symptoms and normalization of
serology [10]. In our experience, when ATTG antibodies
were higher than 100 U/l, histology always showed a
mucosal atrophy (MARSH 3a-3c), except for one case.
The biopsy in children is an invasive exam, even if always
well-tolerated, and often requires sedation. Some authors
propose to postpone biopsy in symptomatic children with
highly positive ATTG, to start a gluten-free diet for some
months and to make the biopsy only if symptoms persist.
Currently, population screening needs biopsy to make the
definitive diagnosis, because subject are asymptomatic. We
suggest to postpone the biopsy when serology values are
borderline (ATTG < 3 times normal), follow up the child
at a free diet, repeating ATTG every 6–12 months and
evaluating the appearance of symptoms. Some cases of
spontaneous normalization of serology are described in
literature, as we also experienced.
Conclusions
The screening program brought to an increased awareness
of doctors and education of people about celiac disease.
“The screening program amplified itself” because often
non-symptomatic relatives of children affected were inves-
tigated and diagnosed for celiac disease.
ATTG is the gold standard for screening, it has the
same sensibility of EMA and it is less expensive: we found
a concordance between ATTG and EMA of 100%. When
ATTG values were less than 3 times normal (<20 U/l),
EMA were borderline. In our experience, 1 child on 5
(20%) even if symptomatic, would have not received
the diagnosis if only AGA IgA and IgG tests were used.
Histology always confirmed ATTG and EMA test, except
for 4 cases, which were diagnosed few years later by means
of follow-up.
General prevalence of celiac disease in Republic of San
Marino is comparable to other countries of North Europe(about 1:100); nonetheless the value tends to increase, as
ATTG (used since 2006) reveals having found about 4
non-symptomatic celiac 6-years-old children on 250 tested
every year, we can state that in some years the general
prevalence will be next to 1:50.
However we can not conclude that there is an increasing
of diagnosis of celiac disease, because ATTG was intro-
duced in 2006 and population screened from 2006 to 2010
is not relevant, yet.
In the end, the screening is not too expensive: about
5000 euros for 250 children yearly for ATTG and total
IgA (about 20 euros per child). If included in ordinary
paediatric visits it’s easy to promote and compliance is
good.
Issues still open are the diagnosis and follow-up of
non-symptomatic patients with a positive serology and
a normal or not diagnostic histology (MARSH 1–2)
and management of subjects with IgA deficiency. In a
future perspective a non-invasive test replacing biopsy
for a definitive diagnosis in non-symptomatic children
is auspicable.
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